OBJECTIVES: To investigate CD25(-)FOXP3(+) cells in RA patients and their possible relationship with disease features and response to glucocorticoids (GCs). METHODS: Peripheral blood mononuclear cells were collected from 147 RA patients, 29 healthy controls and 75 SLE patients as disease controls. The proportion of CD4(+)FOXP3(+) cells with negative, low or high CD25 expression and the levels of IL-10-, TNF-α-, IL-17- and IFNγ-producing cells were assessed by flow cytometry. The presence of the high IL-10 genotype (-1082GG), associated with good response to GC, was determined by PCR amplification and hybridization with allele-specific fluorescently labelled probes. Data were related to treatment and clinical parameters. RESULTS: The CD25(-)FOXP3(+) population was significantly increased in RA patients and negatively correlated with DAS-28 and other disease parameters. The IL-10 genotype did not influence the frequency of these cells in controls or the entire RA group; however, GC-treated patient carriers of the high IL-10 genotype presented significantly higher levels of this population in addition to an increased percentage of IL-10-secreting cells and relatively low amounts of TNF-α-, IFN-γ- and IL-17-positive cells. Finally, a prospective study confirmed that genetically high IL-10 producers significantly increase CD25(-)FOXP3(+) cells after 6 months of GC treatment. CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA.
OBJECTIVES: To investigate CD25(-)FOXP3(+) cells in RApatients and their possible relationship with disease features and response to glucocorticoids (GCs). METHODS: Peripheral blood mononuclear cells were collected from 147 RApatients, 29 healthy controls and 75 SLEpatients as disease controls. The proportion of CD4(+)FOXP3(+) cells with negative, low or high CD25 expression and the levels of IL-10-, TNF-α-, IL-17- and IFNγ-producing cells were assessed by flow cytometry. The presence of the high IL-10 genotype (-1082GG), associated with good response to GC, was determined by PCR amplification and hybridization with allele-specific fluorescently labelled probes. Data were related to treatment and clinical parameters. RESULTS: The CD25(-)FOXP3(+) population was significantly increased in RApatients and negatively correlated with DAS-28 and other disease parameters. The IL-10 genotype did not influence the frequency of these cells in controls or the entire RA group; however, GC-treated patient carriers of the high IL-10 genotype presented significantly higher levels of this population in addition to an increased percentage of IL-10-secreting cells and relatively low amounts of TNF-α-, IFN-γ- and IL-17-positive cells. Finally, a prospective study confirmed that genetically high IL-10 producers significantly increase CD25(-)FOXP3(+) cells after 6 months of GC treatment. CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RApatients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA.
Authors: Markus Bosmann; Fabien Meta; Robert Ruemmler; Mikel D Haggadone; J Vidya Sarma; Firas S Zetoune; Peter A Ward Journal: Am J Pathol Date: 2013-04 Impact factor: 4.307
Authors: Johannes Fessler; Andrea Raicht; Rusmir Husic; Anja Ficjan; Christine Schwarz; Christina Duftner; Wolfgang Schwinger; Winfried B Graninger; Martin H Stradner; Christian Dejaco Journal: Front Immunol Date: 2017-03-20 Impact factor: 7.561
Authors: Ricardo C Ferreira; Henry Z Simons; Whitney S Thompson; Daniel B Rainbow; Xin Yang; Antony J Cutler; Joao Oliveira; Xaquin Castro Dopico; Deborah J Smyth; Natalia Savinykh; Meghavi Mashar; Tim J Vyse; David B Dunger; Helen Baxendale; Anita Chandra; Chris Wallace; John A Todd; Linda S Wicker; Marcin L Pekalski Journal: J Autoimmun Date: 2017-07-23 Impact factor: 7.094
Authors: Lourdes Rocamora-Reverte; Selma Tuzlak; Laura von Raffay; Marcel Tisch; Heidi Fiegl; Mathias Drach; Holger M Reichardt; Andreas Villunger; Denise Tischner; G Jan Wiegers Journal: Front Immunol Date: 2019-03-18 Impact factor: 7.561